Zentalis Gets FDA Fast-Track Designation for Azenosertib

Dow Jones

Jan 09

By Colin Kellaher

Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein.

The San Diego clinical-stage biopharmaceutical company on Thursday said the designation covers azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who are positive via Cyclin E1 immunohistochemistry for protein levels.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Zentalis said Cyclin E1-positive ovarian cancer has historically been associated with resistance to chemotherapy and poor patient outcomes.

The company is currently evaluating azenosertib as a monotherapy and in combination with clinical studies in ovarian cancer and other tumor types.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 09, 2025 07:21 ET (12:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502016535"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502016535\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502016535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502016535","market":"other","top_or_hot":-1,"title":"Zentalis Gets FDA Fast-Track Designation for Azenosertib","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein. \n</p>\n<p>\n  The San Diego clinical-stage biopharmaceutical company on Thursday said the designation covers azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who are positive via Cyclin E1 immunohistochemistry for protein levels. \n</p>\n<p>\n  The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. \n</p>\n<p>\n  Zentalis said Cyclin E1-positive ovarian cancer has historically been associated with resistance to chemotherapy and poor patient outcomes. \n</p>\n<p>\n  The company is currently evaluating azenosertib as a monotherapy and in combination with clinical studies in ovarian cancer and other tumor types. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 07:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zentalis Gets FDA Fast-Track Designation for Azenosertib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZentalis Gets FDA Fast-Track Designation for Azenosertib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 20:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein. \n</p>\n<p>\n  The San Diego clinical-stage biopharmaceutical company on Thursday said the designation covers azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who are positive via Cyclin E1 immunohistochemistry for protein levels. \n</p>\n<p>\n  The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. \n</p>\n<p>\n  Zentalis said Cyclin E1-positive ovarian cancer has historically been associated with resistance to chemotherapy and poor patient outcomes. \n</p>\n<p>\n  The company is currently evaluating azenosertib as a monotherapy and in combination with clinical studies in ovarian cancer and other tumor types. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 07:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZNTL","symbol_name":"Zentalis Pharmaceuticals, LLC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502016535","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502016535","pubTimestamp":1736425260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein.The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.Zentalis said Cyclin E1-positive ovarian cancer has historically been associated with resistance to chemotherapy and poor patient outcomes.The company is currently evaluating azenosertib as a monotherapy and in combination with clinical studies in ovarian cancer and other tumor types.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZNTL":"Zentalis Pharmaceuticals, LLC","BK4567":"ESG概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4139":"生物科技","BK4104":"贸易公司与经销商","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","FAST":"快扣"},"translate_title":"Zentalis获得FDA azenosertib快速通道指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"ZNTL":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 protein. \n\n\n  The San Diego clinical-stage biopharmaceutical company on Thursday said the designation covers azenosertib for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who are positive via Cyclin E1 immunohistochemistry for protein levels. \n\n\n  The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. \n\n\n  Zentalis said Cyclin E1-positive ovarian cancer has historically been associated with resistance to chemotherapy and poor patient outcomes. \n\n\n  The company is currently evaluating azenosertib as a monotherapy and in combination with clinical studies in ovarian cancer and other tumor types. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2025 07:21 ET (12:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}